Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 3132-3137

  Gertz, Morie A ^a   Leung, Nelson ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Zeldenrust, Steven R ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Dingli, David ^a   Greipp, Philip R ^a   Kumar, Shaji K ^a   Lust, John A ^a   Rajkumar, S Vincent ^a   Russell, Stephen J ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Dialysis; Immunoglobulin light chains; Proteinuria; Renal failure

Indexed keywords

CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; EUPHORIA; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSOMNIA; KAPLAN MEIER METHOD; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WITHDRAWAL SYNDROME;

AGED; AMYLOIDOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; MALE; MIDDLE AGED;

EID: 70349488292     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp201     Document Type: Article

References (24)

1. Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Contrib Nephrol 2007; 153: 195-210
2. Obici L, Perfetti V, Palladini G et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22
3. Bollee G, Guery B, Joly D et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 2008; 3: 375-381
4. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melpha-lan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262-267
5. Gertz MA, Lacy MQ, Lust JA et al. Phase II trial of high-dose dex-amethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999; 16: 104-109
6. Gertz MA, Lacy MQ, Lust JA et al. Phase II trial of high-dose dex-amethasone for previously treated immunoglobulin light-chain amy-loidosis. Am J Hematol 1999; 61: 115-119
7. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257-262
8. GertzMA, ComenzoR,Falk RHet al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328
9. Copeland JN, Kouides PA, Grieff M et al. Metachronous development of nonamyloidogenic lambda light chain deposition disease and IgG heavy chain amyloidosis in the same patient. Am J Surg Pathol 2003; 27: 1477-1482
10. U.S. Renal Data System, USRDS. Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006: 76-79
11. Brown JH, Maxwell AP, Bruce I et al. Renal replacement therapy in multiple myeloma and systemic amyloidosis. Ir J Med Sci 1993; 162: 213-217
12. Moroni G, Banfi G, Montoli A et al. Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy. Clin Nephrol 1992; 38: 81-85
13. Montseny JJ, Kleinknecht D, Meyrier A et al. Long-term outcome accordingto renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998; 13: 1438-1445
14. Ozdemir BH, Ozdemir FN, Sezer S et al. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis. Transplant Proc 2006; 38: 432-434
15. Kuroda T, Tanabe N, Sato H et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 2006; 26: 1147-1153 (Pubitemid 44450853)
16. Esteve V, Almirall J, Ponz E et al. Renal involvement in amyloidosis: clinical outcomes, evolution and survival. Nefrologia 2006; 26: 212-217. Spanish
17. Ensari C, Ensari A, Tumer N et al. Clinicopathological and epidemi-ological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant 2005; 20: 1721-1725
18. Gertz MA, Kyle RA, O'Fallon WM. Dialysis support of patients with primary systemic amyloidosis: a study of 211 patients. Arch Intern Med 1992; 152: 2245-2250
19. Leung N, Slezak JM, Bergstralh EJ et al. Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloi-dosis during stem cell transplantation. Am J Kidney Dis 2005; 45: 102-111 (Pubitemid 40038050)
20. Gertz MA, Lacy MQ, Dispenzieri A et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025-1031
21. Lebovic D, Hoffman J, Levine BM et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369-373
22. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dex-amethasone. Haematologica 2007; 92: 1351-1358
23. Bergesio F, Ciciani AM, Manganaro M et al. Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941-951
24. Veeramachaneni R, Gu X, Herrera GA. Atypical amyloidosis: diagnostic challenges and the role of immunoelectron microscopy in diagnosis. Ultrastruct Pathol 2004; 28: 75-82